TY  - CONF

T1  - 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.

JO  - Journal of Clinical Oncology

PY  - 2014/05/20

AU  - Parker C

AU  - Vogelzang NJ

AU  - Sartor AO

AU  - Bottomley D

AU  - Coleman RE

AU  - Skjorestad I

AU  - Wahba M

AU  - Nilsson S

ED  - 

DO  - DOI: 10.1200/jco.2014.32.15_suppl.5070

PB  - American Society of Clinical Oncology (ASCO)

VL  - 32

IS  - 15_suppl

SP  - 5070

EP  - 5070

Y2  - 2025/10/10

ER  -